You searched for Antibody candidate - Page 8 of 69 - Labiotech.eu

News and Trends 24 Nov 2015

2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease?

…review, but recent news has obviously since improved upon these drug targets. Just last month Nestle announced a new research partnership with AC Immune, for their Tau-targeting antibody candidate. AC…

November 24, 2015 - 9 minutesmins - By Dani Bancroft

News and Trends 10 Aug 2022

Captor Therapeutics names lead candidate in fight against hepatocellular carcinoma

…of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization. The CDMO will produce sufficient amounts of drug candidate to complete…

August 10, 2022 - 3 minutesmins - By Liza Laws

Biotech company finland

Best in Biotech 23 May 2025

Finland: Pushing biotech forward in the land of a thousand lakes

…the country’s landscape. Here are nine biotech companies pushing the industry forward in Finland. Table of contents Aplagon Foundation: 2009 Lead candidate: APAC Recent news: Secured a €7 million funding…

May 23, 2025 - 10 minutesmins - By Jules Adam

CAR T therapy companies

Best in Biotech 21 Mar 2024

Eight CAR-T cell therapy companies you should know about

…offering, American company CARGO Therapeutics has begun a phase 2 trial for its lead CAR-T cell therapy candidate CRG-022. The candidate targets CD22, a B-cell specific antigen that is expressed…

March 21, 2024 - 9 minutesmins - By Roohi Mariam Peter

ADVERTISEMENT

danuglipron

In Depth 24 Jul 2024

Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?

…advance the development of this candidate. This comes after the clinical evaluation of several modified-release once-daily formulations of danuglipron resulted in “encouraging pharmacokinetic data” for several candidates, with one showing…

July 24, 2024 - 10 minutesmins - By Willow Shah-Neville

T cell engagers

In Depth 18 Feb 2025

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

…lurking? At present, there are a number of T cell engagers in the clinic. California-based Janux Therapeutics has two candidates in phase 1 trials. Its lead candidate JANX007 is designed…

February 18, 2025 - 10 minutesmins - By Roohi Mariam Peter

numab intarcia autoimmune disease

News and Trends 31 Mar 2020

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant

…rights to develop and commercialize an immuno-oncology drug candidate for an unspecified indication using Numab’s multi-specific antibody platform, MATCH. Antibody-based therapies are becoming increasingly popular in oncology, with Merck’s approved…

March 31, 2020 - 3 minutesmins - By David Kirk

shutterstock 489467578

News and Trends 16 Jan 2017

German Antibody for Cancer Diagnostics catches an Australian Eye

…Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the CAIX antigen on clear cell…

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Memo Therapeutics Antibody

News and Trends 29 Aug 2019

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

…also fuel the expansion of HiFiBiO’s antibody production technology, which is based on screening hundreds of single immune cells at a time for the most effective antibody drug candidate. HiFiBiO…

August 29, 2019 - 2 minutesmins - By Jonathan Smith

nsclc therapies

In Depth 30 Apr 2025

The future of NSCLC treatment: what’s in store for the therapeutic space?

…candidates in the clinic trying to combat this inadequacy. And some of the candidates could be on their way beyond the clinic, as they are being evaluated in late-stage trials….

April 30, 2025 - 12 minutesmins - By Roohi Mariam Peter

biotech cambridge cluster

Best in Biotech 30 Jan 2017

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

…shown significant advantages over antibody-drug conjugates in preclinical models. Clinical trials for the first candidate are due to start in 2017. Acacia Pharma focuses on conditions caused by aggressive therapies,…

January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro

Biotech news

Weekly Roundup 24 Nov 2023

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

…an antibody that was discovered based on WuXi Bio’s integrated technology platforms, so that Myricx can develop an ADC using the antibody, to target solid tumors, through its NMT-1 platform….

November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter